Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Clobetasol Oil in Pediatric AD
NCT03847389Phase 2Terminated
- Start
- Sep 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clobetasol in atopic dermatitis (AD). Primary endpoints: Number of Participants With HPA Axis Suppression - Serum Cortisol Concentration at Day 15 and Adverse Events, Including Treatment Emergent Adverse Events (TEAEs) at Day 15. Started Sep 2019; status: terminated.
02
Drugs
clobetasol
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03847389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03847389.